paroxetine has been researched along with dronabinol in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 5 (50.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
González, MI; Leret, ML; Molina-Holgado, E; Molina-Holgado, F; Reader, TA | 1 |
Salerian, AJ | 1 |
Ahl, B; Anghelescu, IG; Wilhelm, R | 1 |
1 review(s) available for paroxetine and dronabinol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for paroxetine and dronabinol
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Distribution of indoleamines and [3H]paroxetine binding in rat brain regions following acute or perinatal delta 9-tetrahydrocannabinol treatments.
Topics: Animals; Brain; Dronabinol; Female; Gyrus Cinguli; Hippocampus; Hydroxyindoleacetic Acid; Hypothalamus, Anterior; Locus Coeruleus; Male; Neostriatum; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Raphe Nuclei; Rats; Rats, Wistar; Serotonin; Substantia Nigra; Tritium | 1993 |
Successful treatment of sexual dysfunction with dronabinol: a case report.
Topics: Adult; Benzodiazepines; Bipolar Disorder; Dronabinol; Female; Humans; Libido; Olanzapine; Paroxetine; Psychotropic Drugs; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome; Valproic Acid | 2004 |
Dextrometorphan-Paroxetine, But Not Dronabinol, Effective for Treatment-Resistant Aggression and Agitation in an Elderly Patient With Lewy Body Dementia.
Topics: Aged; Aggression; Cannabinoid Receptor Agonists; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dronabinol; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Lewy Body Disease; Male; Paroxetine; Psychomotor Agitation | 2017 |